Taranabant

Source: Wikipedia, the free encyclopedia.
Taranabant
Skeletal formula of taranabant
Space-filling model of the taranabant molecule
Clinical data
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • Investigational (failed)
Identifiers
  • N-[(2S,3S)-4-(4-chlorophenyl)-3-(3-cyanophenyl)-2-butanyl]-2-methyl-2-{[5-(trifluoromethyl)-2-pyridinyl]oxy}propanamide
JSmol)
  • C[C@@H]([C@@H](CC1=CC=C(C=C1)Cl)C2=CC=CC(=C2)C#N)NC(=O)C(C)(C)OC3=NC=C(C=C3)C(F)(F)F
  • InChI=1S/C27H25ClF3N3O2/c1-17(34-25(35)26(2,3)36-24-12-9-21(16-33-24)27(29,30)31)23(14-18-7-10-22(28)11-8-18)20-6-4-5-19(13-20)15-32/h4-13,16-17,23H,14H2,1-3H3,(H,34,35)/t17-,23+/m0/s1
  • Key:QLYKJCMUNUWAGO-GAJHUEQPSA-N
  (verify)

Taranabant (codenamed MK-0364) is a

cannabinoid receptor type 1 (CB1) inverse agonist that was investigated as a potential treatment for obesity due to its anorectic effects.[1][2] It was discovered by Merck & Co.

In October 2008, Merck has stopped its

clinical trials with the drugs due to high level of central nervous system side effects, mainly depression and anxiety.[3][4][5][6]

See also

References

  1. PMID 17293109
    .
  2. S2CID 20001781
    .
  3. ^ "Press release by Merck". Retrieved 4 October 2008.
  4. S2CID 6769554
    .
  5. S2CID 23886192
    .
  6. S2CID 23352608
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Taranabant&oldid=1206031233"